CFO & Head of Business Operations
Ted is a finance and operations executive with more than twenty five years of progressive experience serving life science, biotechnology and pharmaceutical companies in both public and private markets. His background includes extensive management and leadership experience in finance, accounting, operations, investor relations, business development, treasury, strategic development and implementation, capital raising and M&A.
Prior to Scholar Rock, Ted served as AMAG’s executive vice president, chief financial officer & chief operating officer. He joined AMAG in 2016 and brings more than 20 years of public and private corporate finance and operational experience in the biotechnology, pharmaceutical and medical device industries.
Prior to joining AMAG, he served in various positions at Ocata Therapeutics, Inc., most recently as chief financial officer and chief operating officer. During his tenure at Ocata, he led the turnaround of the company, which ultimately resulted in its acquisition by Astellas Pharma in February 2016. From 2008 to 2013, Mr. Myles served as chief financial officer and vice president of operations at PrimeraDx, Inc. Mr. Myles also served as controller at EMD Pharmaceuticals, Inc., a wholly-owned subsidiary of Merck KGaA.
Earlier in his career, Mr. Myles was an associate in the healthcare investment banking group at SG Cowen Securities Corporation and was a senior associate in the audit practice of Coopers & Lybrand LLP. Mr. Myles currently serves on the board of directors of Scholar Rock Holdings (NASDAQ: SRRK), a biotechnology company.
Mr. Myles holds a Bachelor of Science in Business Administration BSBA from the University of Hartford and a Master of Business Administration from The John M. Olin School of Business at Washington University.